MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Decision Cover Letter

Decision of the licensing authority to:

accept change(s) to the agreed paediatric investigation plan (MHRA-100605-PIP01-22) and to the deferral.

MHRA-100605-PIP01-22-M01

Scope of the Application

Active Substance(s)

SPARSENTAN

Condition(s)

Treatment of immunoglobulin A nephropathy

Pharmaceutical Form(s)

Film-coated tablet; Age-appropriate oral liquid dosage form (oral suspension)

Route(s) of Administration

ORAL USE

Name / Corporate name of the PIP applicant

Vifor (International) Inc.

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, Vifor (International) Inc. submitted to the licensing authority on 25/04/2025 16:35 BST an application for a Modification

The procedure started on 10/06/2025 13:15 BST

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to accept change(s) to the agreed paediatric investigation plan and to the deferral

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Final Decision Letter

MHRA-100605-PIP01-22-M01

Of 21/08/2025 20:09 BST

On the adopted decision for SPARSENTAN (MHRA-100605-PIP01-22-M01) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on modification of a paediatric investigation plan (including modification of a waiver or deferral included in that paediatric investigation plan)

This decision applies to a Modification for SPARSENTAN, Film-coated tablet; Age-appropriate oral liquid dosage form (oral suspension) , ORAL USE .

This decision is addressed to Vifor (International) Inc. , Rechenstrasse 37, St Gallen, SWITZERLAND, 9001

ANNEX I

1. Waiver

1.1 Condition:

Treatment of immunoglobulin A nephropathy The waiver applies / applied to: Paediatric Subset(s): The paediatric population from birth to less than 2 years of age Pharmaceutical form(s): Tablet Age-appropriate oral liquid dosage form (oral suspension) Route(s) of administration: ORAL USE Reason for granting waiver: on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies(s) are not feasible.

2. Paediatric Investigation Plan:

2.1 Condition(s):

Treatment of immunoglobulin A nephropathy

2.2 Indication(s) targeted by the PIP:

Treatment of immunoglobulin A nephropathy

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

The paediatric population from 2 years to less than 18 years of age

2.4 Pharmaceutical Form(s):

Tablet Age-appropriate oral liquid dosage form (oral suspension)

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	1	Study 1 (FORM-DEV1) Age-appropriate oral liquid dosage form and suitable medical administration device for dosing children 2 years of age and older.
Non-Clinical Studies	0	Not applicable.
Clinical Studies	1	Study 2 (021-PED1) Open-label, uncontrolled, 2-part study to evaluate the pharmacokinetics and pharmacodynamics (part 1: 12-weeks), safety, and efficacy (part 2: 96-weeks) of once daily oral sparsentan (oral liquid suspension formulation) in children from 2 years to less than 18 years of age with immunoglobulin A nephropathy (IgAN), Henoch-Schonlein purpura nephritis (HSPN), or Alport Syndrome.
Extrapolation, Modeling & Simulation Studies	2	Study 3 Physiologically based PK (PBPK) model to assess the impact of the physiochemical properties of a new paediatric oral suspension formulation under conditions of use, to support dose selection for paediatric patients from 2 years of age. Study 4 Population pharmacokinetic (PopPK) modelling and simulation study to evaluate the dose-exposure relationship in adults and in each paediatric subpopulation

		and disease population from 1 to less than 18 years of age.
Other Studies	0	Not applicable.
Other Measures	0	Not applicable.

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	28/02/2027
Deferral of one or more studies contained in the paediatric investigation plan:	Yes